Market Overview

Strategia Holdings Announces Strategic Partnership Alliance with JS InnoPharm (Shanghai) for Global Drug Development

Share:

Strategia Holdings, LLC. announced a strategic partnership
alliance with JS InnoPharm (Shanghai), Ltd. to facilitate global
drug development. Through this partnership, both companies will leverage
their comprehensive knowledge, broad expertise, drug candidates, and
networks in the global development of multiple therapeutics.

"We are very excited about this strategic partnership with JS InnoPharm
in Shanghai. By combining the strengths of JS InnoPharm with
their drug discovery expertise and China network to Strategia Holdings,
LLC, we are creating a new, efficient, streamlined model for
global drug development," said Dr. Keizo Koya, CEO and Founder of Strategia.
"This is an innovative and unique collaboration that will translate the
highest-quality science into proven clinical success in an efficient and
agile manner while enhancing the competitive position of both companies
in the ever-increasing challenging environment of clinical drug
development. The ultimate goal of this partnership is to effectively
deliver new therapeutic approaches to patients worldwide."

The Strategia Holdings group currently consists of three
biopharmaceutical companies; Spirita Oncology, LLC, Mirata BioPharma,
LLC, and Strategia Pharmaceuticals, LLC. All three organizations will
work closely together with JS InnoPharm under the Strategic Partnership
Alliance.

"JS InnoPharm is keen on collaborating with Strategia to establish
long-term commitments to accelerate global drug development with us,"
said Dr. Jintao Zhang, CEO of JS InnoPharm. "We believe in the power of
China and the US coming together and crafting solutions to enhance
efficiencies and achieve faster drug development timelines with higher
success rates. This partnership allows the organizations to work closely
together in a collaborative effort to reach those goals."

About Strategia

Strategia Holdings, LLC, is based in the U.S. and oversees three biotech
companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia
Pharmaceuticals, LLC. Spirita focuses on oncology drug development in
the US with E6201, a MEK1 inhibitor, as their flagship candidate focused
on melanoma brain metastases. Mirata is a pre-clinical stage
immuno-oncology company based on a Targeted Granzyme B Immunotherapy
(TGI) platform. Strategia Pharmaceuticals was established in 2012
consisting of oncology pharma and biotech drug development veterans, and
is a strategic consulting company to assist pharma and biotech clients
develop their oncology portfolios with greater expertise, more
efficiently, more rapidly, translating into lower overall cost to market.

View Comments and Join the Discussion!